First announced in January 2020, Novavax’s (Nasdaq:NVAX) NVX-CoV2373 COVID–19 has won FDA authorization for primary immunization. However, it is presently not authorized as a booster.
NVAX shares ticked up 0.27% to $69.95.
Novavax is late to the COVID-19 vaccine partner, scoring authorization more than a year and a half after Moderna (NYSE:MRNA) and Pfizer (NYSE:PFE) won emergency use authorization for their respective COVID-19 vaccines.
Gaithersburg, Maryland–based Novavax had received a $1.75 billion federal contract to develop and manufacture NVX-CoV2373.
In August, the federal government said it would not provide money for further production until Novavax addressed quality concerns.
Now that the vaccine is authorized, CDC will convene an advisory panel to advise who should obtain the two-dose vaccine.
Before the omicron and delta waves, the Novavax vaccine was 90.4% efficacious in preventing COVID-19 of any severity in. Phase 3 t…